This study is in progress, not accepting new patients
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by John Glaspy (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- John Glaspy (ucla)
Dr. John A. Glaspy holds the Simms/Mann Family Foundation Chair in Integrative Oncology.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- ID
- NCT04401748
- Phase
- Phase 3 Myelodysplastic Syndrome Research Study
- Study Type
- Interventional
- Participants
- About 531 people participating
- Last Updated